In the Netherlands, cervix uteri cancer screening coverage has shown a consistent decline from 2013 to 2023. In 2023, the coverage stood at 52.6 units. Examining year-on-year changes, the coverage peaked in 2013 at 66.2 units but has faced significant drops, with a notably steep decline in 2020 at 49.7 units likely due to the pandemic. The one-year variation between 2022 and 2023 showed a slight increase of 0.19%. Over the last two years, from 2022 to 2023, the screening coverage experienced a modest rise of 1.32%. Looking at the compounded annual growth rate (CAGR) over the past five years, the average annual decline stands at -1.56%, translating to a forecasted overall decline of -7.57% by 2028.
Future trends to watch for include advancements in screening technologies, changes in public health policy, and possible public awareness campaigns that could influence screening rates. Additionally, the integration of AI in diagnostics and potential new healthcare regulations could impact the trajectory of screening coverage.
